REG - Indivior PLC - Director Declaration

IndiviorAnnouncement

11/04/2018 16:05

RNS Number : 6272K
Indivior PLC
11 April 2018
 

Indivior PLC (the 'Company')
 
Indivior PLC confirms that Mr Daniel Tassé, Senior Independent Director, was appointed as an independent director of HLS Therapeutics Inc., a specialty pharmaceutical company listed on the TSX Venture Exchange, with effect from March 14, 2018.
 
This announcement is made in accordance with Listing Rule 9.6.14.
 
Kathryn Hudson
Company Secretary



This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDNFKDDKPBKDDQD